Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis. - Yang, Ming‐Han; Huang, Chiun‐Sheng; Chang, Dwan‐Ying; Hu, Fu‐Chang; Huang, Shu‐Min; Huang, Po‐Hsiang; Chen, I‐Chun; Chen, Tom Wei‐Wu; Lin, Ching‐Hung; Lu, Yen‐Shen (Cancer Medicine, 2024)